Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 9c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.53), $0.09 better than the analyst estimate of ($0.62).

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Macy's (M) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY Guidance
• MasterCraft (MCFT) Tops Q4 EPS by 3c, Beats on Revenue; Offers Guidance
• Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance